Communiqués Arcus Biosciences, Inc.

Actions

RCUS

US03969F1093

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:02 02/09/2026			Varia. 5j.	Varia. 1 janv.
29,85 ^USD	+0,47 %		-2,96 %	+25,26 %

10/08	Le traitement Casdatifan d'Arcus Biosciences pourrait être lancé en 2028, selon Morgan Stanley	MT
10/08	Arcus Biosciences, Inc. : Morgan Stanley conserve son opinion neutre	ZM

Communiqués

26/08	Arcus Biosciences to Participate in Three Upcoming Investor Conferences	BU
11/08	Arcus Biosciences Announces New Employment Inducement Grants	BU
05/08	Arcus Biosciences : Reports Second-Quarter 2026 Financial Results and Provides a P...	PU
05/08	Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update	BU
27/07	Arcus Biosciences Announces New Employment Inducement Grants	BU
22/07	Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients	BU
22/07	Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer	BU
22/07	Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer	BU
21/07	Arcus Biosciences : to Host Conference Call to Discuss Second-Quarter 2026 Financi...	PU
21/07	Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates	BU
09/07	Arcus Biosciences Announces New Employment Inducement Grants	BU
01/07	New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan	BU
24/06	Arcus Biosciences Announces New Employment Inducement Grants	BU
09/06	Arcus Biosciences Announces New Employment Inducement Grants	BU
04/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer	AQ
03/06	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer	BU
26/05	Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	BU
06/05	Arcus Biosciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Arcus Biosciences : Reports First-Quarter 2026 Financial Results and Provides a Pi...	PU
05/05	Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update	BU
27/04	Arcus Biosciences Announces New Employment Inducement Grants	AQ
24/04	Arcus Biosciences Announces New Employment Inducement Grants	BU
21/04	Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates	BU
21/04	Arcus Biosciences : to Host Conference Call to Discuss First-Quarter 2026 Financia...	PU
09/04	Arcus Biosciences Announces New Employment Inducement Grants	BU